Tag Archives: Excel Diagnostics

First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate

Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid.  This is a Phase … Continue reading

Posted in carcinoid, carcinoid and neuroendocrine tumor treatments, clinical trials, neuroendocrine cancer | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

FDA Approves Amendment for PRRT Clinical Trial in Texas

BREAKING NEWS:  The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate in patients who have predominately liver metastasis … Continue reading

Posted in carcinoid, neuroendocrine cancer | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

10 Highlights of the Year 2011 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2011, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community.  Here are 10 of the year’s important stories: 1)     The FDA approved the first … Continue reading

Posted in carcinoid, carcinoid awareness, neuroendocrine cancer awareness, neuroendocrine tumors | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

Worldwide NET Cancer Awareness Day Update: Events from Australia to Europe to North America

Go around the globe for the second Worldwide NET Cancer Awareness Day (WNCAD) on November 10, 2011. Throughout that day, videos featuring NET events and experts will air on http://www.netcancerday.org  as the sun travels west, from Australia to Europe to … Continue reading

Posted in WNCAD, Worldwide NET Awareness Day, Worldwide NET Cancer Awareness Day | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim S. … Continue reading

Posted in carcinoid, carcinoid and neuroendocrine tumor treatments, carcinoid specialists, clinical trials, NET (neuroendocrine tumor) cancer, neuroendocrine cancer, neuroendocrine tumors, nuclear imaging | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)

For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate.   Ebrahim S. Delpassand, MD, chief executive officer and medical director of Excel Diagnostics, has announced that … Continue reading

Posted in carcinoid, carcinoid and neuroendocrine tumor treatments, carcinoid doctors, carcinoid specialists, NET (neuroendocrine tumor) cancer, neuroendocrine cancer, neuroendocrine tumors, nuclear imaging, rare cancers, rare diseases, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 19 Comments